Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

First patient dosed in phase IIb study of Lomecel-B in hypoplastic left heart syndrome

July 7, 2021

DIO2 is a regulator of mitochondrial activity in developing human cardiomyocytes

July 7, 2021

Downregulation of ERBB4 leads to peripartum cardiomyopathy

July 6, 2021

Vivavision Biotechnology describes new ROCK2 inhibitors

July 6, 2021

Model of diastolic dysfunction with preserved ejection fraction developed to test HDAC6 inhibition

July 6, 2021

Alnylam initiates phase II study of zilebesiran for mild to moderate hypertension

June 30, 2021

Loss-of-function mutations in IPO8 lead to syndromic thoracic aortic aneurysm

June 30, 2021

First patients enrolled in IMPROVE-DiCE study of IMB-101

June 23, 2021

Sirtuin affects cardiac lipotoxicity via secondary mechanism

June 15, 2021

IMDC recommends continuation of phase IIb study of nangibotide in septic shock

June 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...